High-quality reports and their characteristics in the Japanese Adverse Drug Event Report database (JADER)

Purpose: Spontaneous adverse drug reaction reporting is the foundation of postmarketing drug safety monitoring. The present study aimed to analyze and clarify the quality and characteristics of the Japanese Adverse Drug Event Report database (JADER) using the World Health Organization (WHO) documentation grading scheme and the vigiGrade completeness score. The characteristics of reports were described using both schemes simultaneously. The way of proper use of these two schemes was explored. Methods: The WHO documentation grading scheme and the vigiGrade completeness score were applied to the same dataset (JADER202001 dataset). Reports classified as high-quality under both assessment criteria were extracted, and the characteristics of these reports were analyzed. Results: Of the 607,361 adverse drug reaction reports analyzed, 52.8% were ‘well-documented reports’ with a vigiGrade completeness score >0.8. Under the WHO documentation grading scheme, 328,702 reports (54.1%) were Grade 2 and 5,178 (0.9%) were Grade 3 (including rechallenge information). Among well-documented Grade 3 reports, classified as the highest quality, a high proportion of the adverse drug reaction reports were related to disorders of hematopoietic function resulting from anticancer drugs. Because a high proportion of the reports with rechallenge information were for anticancer drugs as suspect drugs, the WHO documentation grading scheme tended to extract reports regarding anticancer drugs as high quality. Conclusions: We conclude that the two schemes need to be used appropriately, depending on the purpose of analysis, the target adverse drug reactions, and suspect drugs.

[1]  M. Miyazaki,et al.  The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade , 2020, International Journal of Clinical Pharmacy.

[2]  T. Sakai,et al.  Quality evaluation of the Japanese Adverse Drug Event Report database (JADER) , 2019, Pharmacoepidemiology and drug safety.

[3]  T. Tomita,et al.  Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis , 2019, Modern rheumatology.

[4]  N. Gogtay,et al.  An analysis of completeness and quality of adverse drug reaction reports at an adverse drug reaction monitoring centre in Western India , 2018, Perspectives in clinical research.

[5]  Albert Figueras,et al.  Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia—a restraint to the potentiality for signal detection , 2017, European Journal of Clinical Pharmacology.

[6]  H. Aljadhey,et al.  Completeness of adverse drug reactions reports of the Saudi adverse event reporting system , 2015, Saudi medical journal.

[7]  M. McCarthy Drug makers’ adverse event reports are often incomplete, US report finds , 2015, British medical journal.

[8]  G. Niklas Norén,et al.  vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues , 2013, Drug Safety.

[9]  Betsabé Sánchez-Sánchez,et al.  Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study. , 2012, Drug safety.

[10]  M. Lindquist VigiBase, the WHO Global ICSR Database System: Basic Facts , 2008 .

[11]  Y. Tomita,et al.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. , 2007, The Journal of rheumatology.

[12]  A. Egberts,et al.  Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. , 2001, British journal of clinical pharmacology.

[13]  正博 頭金 医薬品副作用データベース(Japanese Adverse Drug Event Report database:JADER) , 2015 .

[14]  M. Rawlins Monitoring for Drug Safety , 1988 .